NOVITA HEALTHCARE LTD 
By Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121
Telephone 61 3 9208 4300 Facsimile 61 3 9208 4146Website www.avexa.com.au
Company announcement Avexa files to extend ATC patent lifeMelbourne, Australia - 23rd November 2011 - Melbourne-based biotechnology company Avexa Limited [ASX:AVX] today announced that it has filed two new patents covering the company's Apricitabine (ATC) program. The two patents are based around the clinical findings identified by the company following the full analysis of the Phase II/III data set.
Dr Jonathan Coates, Avexa's Interim Chief Executive Officer
and Chief Scientific Officer, said: "These patents have real
commercial application as they are focused on the use of ATC
and its synergistic benefits when taken with either of two
existing marketed drugs. These new patents dramatically
improve the IP position for the company's ATC program".
The success in the treatment of HIV-1 infection by drug
combinations has been known for some time. The results of our
recent studies show that, unexpectedly, a number of marketed
drugs work better with ATC than would have been predicted
from historical knowledge, and considerably better than in
combination with lamivudine, (ViiV's anti-HIV agent also
known as 3TC).
The new filings will add to the existing patent portfolio for
ATC and could potentially provide patent protection for the
ATC program. The filings have only recently been submitted;
the company will continue to update shareholders on the
progress of these filings, as well as other activities around
the ATC program.
"The use of these new findings is one example of how Avexa is
working to add shareholder value and increase the potential
of the ATC program, while keeping expenditure under control,"
said Avexa's Chairman Mr Iain Kirkwood.
For more information: | ||
Mr Iain Kirkwood Chairman Avexa Ph: +61 3 9208 4300 | Dr Jonathan Coates Interim CEO & CSO Ph: +61 3 9208 4300 | Richard Allen Oxygen Financial Public Relations Ph: + 61 3 9915 6341 |
Avexa Limited (www.avexa.com.au) is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa's key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.
www.avexa.com.au
| distribué par | Ce noodl a été diffusé par Avexa Limited et initialement mise en ligne sur le site http://www.avexa.com.au. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-11 04:20:46 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
| Documents associés | |
| Avexa files to extend ATC patent life |
